Pazopanib for Metastatic Alveolar Soft Part Sarcoma
Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Alveolar soft part sarcoma (ASPS), a rare subset of STS (<1%) harbors t(X;17)(p11;q25)
translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high
expression of angiogenic factors, sunitinib and cediranib produced overall response rates of
55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Asan Medical Center Samsung Medical Center Seoul National University Bundang Hospital Severance Hospital